Answers are grounded in this paper and cite their sources.
Spinal muscular atrophy (SMA) is a devastating disorder caused by mutations in the gene encoding survival motor neuron (SMN), a protein essential to multiple cellular homeostatic functions. SMN-deficient motor neurons die, leading to progressive muscle atrophy and weakness. Traditionally, the most severe phenotype, type 1 SMA, was characterized by an early dependence on mechanical ventilation,1 generalized weakness with inability to roll or sit independently,2 and early death (< 2 years).1 However, earlier diagnosis through newborn screening and approval of disease modifying therapies are unfolding a new era for SMA: new prognosis and new disease phenotypes. The Perspective article published in PTJ by Krosschell et al3 summarized recent developments in SMA, leading to the commercial approval of new disease-modifying therapies. The implementation of these therapies profoundly improved survival of type 1 SMA and offered potential to preserve independent breathing and acquire new developmental milestones.4 With the emergence of viable treatments, many states have enacted newborn screening for SMA to rapidly detect the condition and intervene while infants remain asymptomatic, potentially preserving motor neuron survival and prolonging independence.5 People with less aggressive types of SMA who received newly approved treatments also achieved more stable disease activity and potential for functional gain.6 Coincident with this emerging course of SMA is the need to disseminate knowledge and share resources with clinical providers. Krosschell and colleagues outlined the thoughtful, coordinated approach undertaken via the partnership of industry, academia, clinician experts, and patient advocacy groups to promote knowledge translation. Fundamental knowledge translation approaches included an idea needs assessment, creation of an SMA toolkit for both research therapists and practicing clinicians, and development of a training pipeline through advocacy groups and professional community engagement. Although the resources developed by Krosschell et al offer value for research, they can also serve to inform best clinical management practices, as we begin to understand how newly approved treatments impact longer-term changes in development and function. The authors emphasized an ongoing need to disseminate more broadly clinical guidelines for physical therapist management of SMA, to incorporate recommended standard outcome measures into routine practice, and to conduct research on the effects of physical therapist interventions on the emerging new SMA phenotypes. The call to action by Krosschell et al requires physical therapists to view SMA with fresh eyes. One important aspect of this fresh perspective is the need for posttreatment natural history studies. Although not required for post-approval federal oversight, the careful, objective tracking of function will help us understand the prevalence and severity of emerging issues in treated patients. For example, although children with treated type 1 SMA may sustain independent breathing for a longer time, our team noted clinically significant sleep breathing dysfunction in many.7 Development of a more “flexible” outcome measure should also be considered, due to ceiling effects and low sensitivity of historical SMA outcome measures.8,9 For example, the CHOP Intend, the scale used to receive gene replacement therapy approval, plateaued even as patients reached new motor milestones. Clearly, SMA necessitates new rating measures to capture the patient’s motor function gain. As movement experts, physical therapists are the natural choice to develop, validate, implement, and advocate for new outcome measures that will capture this emerging phenotype. We are in a unique position; the disease we learned about as student physical therapists has shape-shifted. Our teaching approaches and clinical practice must evolve as well. We must also broaden our vision beyond SMA. More than 7000 conditions are designated as rare diseases, and, even though condition each has a low incidence, combined they represent an estimated 25 to 30 million Americans. Many of the conditions lead to progressive disability and early mortality. Although more than 90% of rare diseases currently lack an approved treatment, change is on the horizon. By 2030, approval of more than 60 additional durable gene and cell therapies will enable disease-modifying treatment of approximately 93,000 patients for a variety of rare diseases.10 Academic centers serve as the conduits for much of this clinical research, but we must turn our attention to knowledge translation for practicing clinicians, particularly those in rural, urban, or socioeconomically disadvantaged regions. These emerging therapies, either newly approved or under late-stage clinical trials, will fundamentally alter the course of many diseases and change physical therapist clinical practice in these areas. Physical therapists can and should play a central role in this knowledge translation call to action. Knowledge translation in rare disease will require interprofessional efforts from physical therapist in conjunction with physicians, occupational therapists, speech language pathologists, nurses, clinical coordinators, patients and their families, and educators. Physical therapists have the knowledge and skills to contribute to the knowledge translation process from research to clinical care in a meaningful way and to train practicing clinicians, students and educators, and other stakeholders. As the movement experts, we should be prepared to answer the call. Concept/idea/research design: B.K. Smith Writing: B.K. Smith, M. Corti The authors completed the ICMJE Form for Disclosure of Potential Conflicts of Interest and reported no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: